NBIX vs STRO · P/E 45, rev $2.36B vs rev $62.0M
Neurocrine Biosciences Inc (NBIX) versus Sutro Biopharma (STRO) — a side-by-side from cached financials, not a winner call.
Neurocrine Biosciences Inc (NBIX) is a drug manufacturers - specialty & generic company listed on US.
Sutro Biopharma (STRO) is a biotechnology company listed on NASDAQ.
Latest reported NBIX revenue for 2024-12-31 was $2.36B. Net income was $341.3M. Revenue was up 24.8% from 2023-12-31 to 2024-12-31. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
Latest reported STRO revenue for 2024-12-31 was $62.0M. Net income was -$227.5M. Revenue was down 59.6% from 2023-12-31 to 2024-12-31. STRO currently screens at market cap $470.8M.
NBIX currently screens at market cap $13.21B and trailing P/E 45.2. STRO currently screens at market cap $470.8M.
Not investment advice. Open the NBIX and STRO stock pages for the full models.
Not investment advice.